Deutsche Bank Maintains a 'Buy' on Gilead Sciences (GILD); HIV Scripts Up in First Weeks of Q3

Deutsche Bank maintains a 'Buy' on Gilead Sciences (NASDAQ: GILD) price target of $65.00.

Analyst, Robyn Karnauskas, said, "GILD HIV scripts tracking up for first five weeks in 3Q12 vs. first five weeks in 2Q12...These trends are based on cumulative 5 weeks of scripts for GILD’s HIV franchise."

Atripla scripts are up 0.8% QoQ and up 2.7% YoY; Truvada scripts are up 2.8% QoQ and up 5.0% YoY; Viread scripts are up 3.5% QoQ and up 5.6% YoY; Emtriva scripts are up 0.4% QoQ and up 2.5% YoY; Complera scripts are up 109.7% QoQ.

For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.

Shares of Gilead Sciences closed at $56.77 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• UBS Reiterates Buy Rating on HF Sinclair (DINO)
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy